Dalpiciclib in HR+/HER2- ABC
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
- EligibilityCriteria: Inclusion Criteria:  Histologically confirmed advanced breast cancer Hormone receptor-positive and human epidermal growth factor receptor 2-negative ECOG 0-1  Exclusion Criteria:  Pregnant or breastfeeding History of immunodeficiency - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer - SamplingMethod: Non-Probability Sample